SAN FRANCISCO—The first proof-of-concept trial of its kind has concluded that perioperative administration of a human plasma fraction retrieved from young donors modulates the inflammatory response to surgery in patients undergoing primary total hip or knee arthroplasty.
In addition to these proteomic and immunologic results, investigators found that patients who received the agent GFR6021 (Alkahest/Grifols) also demonstrated trends toward improved clinical recovery, although the